JEWEL-I

Not Applicable

Completed

• Conditions: Advanced NSCLC

• Registration Number: JPRN-jRCT1080224859
• Lead Sponsor: MSD K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-09-06
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: completed
• Sex: All
• Target Recruitment: 2300

Inclusion Criteria

a. Patient started first-line systemic anti-cancer treatment for advanced NSCLC (stage IIIB-C/IV) at a participating center from July 1, 2017 through December 20, 2018 (retrospective identification in Cohort 1) or patient will start first-line systemic anti-cancer treatment for advanced NSCLC (stage IIIB-C/IV) at a participating center during the enrollment period (prospective identification in Cohort 2).
b. Patient's advanced NSCLC diagnosis was histologically or cytologically confirmed prior to starting systemic anti-cancer treatment.
c. Patient is at least 20 years of age at diagnosis of advanced NSCLC.
d. Informed consent requirements or other requirements set forth by the local ethics committee have been met for patient.
e. Patient has PD-L1 results available on or before the index date (Cohort 1 only)

Exclusion Criteria

a.Patient received/will receive first-line systemic anti-cancer treatment as a clinical trial participant.
b.Patient has tumors with actionable gene alterations with results documented on or before the index date (Cohort 1) or at the time of enrollment (Cohort 2).
c.Investigator determines the patient is ineligible due to incomplete medical records on the index date (Cohort 1) or at the time of enrollment (Cohort 2).

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
other<br>1.To describe real-world treatment patterns for advanced NSCLC by line of therapy.<br>2.To describe real-world clinical outcomes for treatment of advanced NSCLC by line of therapy and regimen type. <br>3.To describe health care resource utilization (HCRU) associated with pre-specified clinical reasons, disease management, and drug use/administration for advanced NSCLC patients by line of therapy and regimen type.

Secondary Outcome Measures

Name	Time	Method
other<br>-